Liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist, produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae, has been engineered to be 97% homologous to native human GLP-1 by substituting argin
The trademark office will issue the notice on providing evidence of the use of the registered trademark to the registrant. At this time, the trademark holder can submit evidence of the actual use of the registered trademark within 2 months from the date o